IMDX vs SPGI · rev $271.0K vs P/E 27, rev $15.34B
Insight Molecular Diagnostics Inc. (IMDX) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
IMDX currently screens at market cap $0. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the IMDX and SPGI stock pages for the full models.
Not investment advice.